News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
67,740 Results
Type
Article (5763)
Company Profile (15)
Press Release (61962)
Section
Business (25303)
Career Advice (159)
Deals (4281)
Drug Delivery (46)
Drug Development (6516)
Employer Resources (18)
FDA (1198)
Job Trends (1681)
News (36048)
Policy (2235)
Tag
2024 BioCapital Digital (1)
2024 BioMidwest Digital (1)
2024 Biotech Bay Standard (3)
2024 Biotech Beach Standard (2)
2024 Genetown Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
Academia (281)
Adcomms (3)
Allergies (3)
Alliances (6128)
ALS (11)
Alzheimer's disease (254)
Antibody-drug conjugate (ADC) (18)
Approvals (1180)
Artificial intelligence (46)
Autoimmune disease (3)
Bankruptcy (34)
Best Places to Work (1263)
BIOSECURE Act (4)
Biosimilars (11)
Biotechnology (14)
Bladder cancer (4)
Brain cancer (1)
Breast cancer (22)
Cancer (179)
Cardiovascular disease (31)
Career advice (127)
Career pathing (6)
CAR-T (15)
Cell therapy (45)
Clinical research (4927)
Collaboration (116)
Compensation (3)
Complete response letters (1)
COVID-19 (334)
CRISPR (5)
C-suite (50)
Cystic fibrosis (15)
Data (151)
Denatured (2)
Depression (7)
Diabetes (83)
Diagnostics (631)
Digital health (4)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (27)
Drug pricing (41)
Drug shortages (23)
Duchenne muscular dystrophy (8)
Earnings (5367)
Editorial (19)
Employer branding (1)
Employer resources (16)
Events (6337)
Executive appointments (141)
FDA (1279)
Featured Employer (3)
Friedreich's ataxia (1)
Frontotemporal dementia (1)
Funding (352)
Gene editing (15)
Generative AI (5)
Gene therapy (48)
GLP-1 (410)
Government (355)
Guidances (5)
Healthcare (1542)
Huntington's disease (2)
IgA nephropathy (4)
Immunology and inflammation (25)
Indications (2)
Infectious disease (344)
Inflammatory bowel disease (24)
Inflation Reduction Act (7)
Influenza (1)
Intellectual property (12)
Interviews (24)
IPO (1961)
IRA (15)
Job creations (462)
Job search strategy (121)
Labor market (7)
Layoffs (62)
Leadership (3)
Legal (513)
Liver cancer (5)
Lung cancer (24)
Lymphoma (9)
Machine learning (1)
Management (5)
Manufacturing (72)
MASH (20)
Medical device (1329)
Medtech (1331)
Mergers & acquisitions (2385)
Metabolic disorders (305)
Multiple sclerosis (4)
NASH (7)
Neurodegenerative disease (22)
Neuropsychiatric disorders (3)
Neuroscience (301)
NextGen: Class of 2025 (1068)
Non-profit (368)
Northern California (271)
Now hiring (17)
Obesity (210)
Opinion (85)
Ovarian cancer (6)
Pain (10)
Pancreatic cancer (3)
Parkinson's disease (10)
Partnered (5)
Patents (9)
Patient recruitment (11)
Peanut (3)
People (10356)
Pharmaceutical (5)
Pharmacy benefit managers (2)
Phase I (1528)
Phase II (2062)
Phase III (1840)
Pipeline (92)
Podcasts (37)
Policy (39)
Postmarket research (241)
Preclinical (694)
Press Release (6)
Prostate cancer (8)
Psychedelics (6)
Radiopharmaceuticals (43)
Rare diseases (42)
Real estate (660)
Recruiting (7)
Regulatory (1577)
Reports (5)
Research institute (212)
Resumes & cover letters (22)
RNA editing (1)
RSV (2)
Schizophrenia (10)
Series A (95)
Series B (68)
Service/supplier (1)
Sickle cell disease (3)
Southern California (192)
Special edition (8)
Spinal muscular atrophy (2)
Sponsored (2)
Startups (2206)
Supply chain (21)
The Weekly (34)
United States (1800)
Vaccines (41)
Venture capitalists (35)
Webinars (6)
Weight loss (210)
Women's health (2)
Date
Today (22)
Last 7 days (76)
Last 30 days (303)
Last 365 days (3688)
2025 (924)
2024 (3774)
2023 (3813)
2022 (6594)
2021 (5996)
2020 (5679)
2019 (5196)
2018 (4048)
2017 (3584)
2016 (3004)
2015 (3426)
2014 (2467)
2013 (2092)
2012 (2191)
2011 (2445)
2010 (2470)
Location
Africa (93)
Alabama (7)
Alaska (2)
Arizona (10)
Arkansas (5)
Asia (4979)
Australia (590)
California (565)
Canada (430)
China (95)
Colorado (21)
Connecticut (25)
Delaware (9)
Europe (9609)
Florida (34)
Georgia (14)
Idaho (5)
Illinois (43)
India (7)
Indiana (127)
Iowa (2)
Japan (25)
Kansas (7)
Kentucky (1)
Louisiana (4)
Maine (6)
Maryland (54)
Massachusetts (341)
Michigan (10)
Minnesota (16)
Missouri (10)
Nebraska (1)
Nevada (2)
New Hampshire (5)
New Jersey (91)
New Mexico (4)
New York (131)
North Carolina (78)
Northern California (271)
Ohio (38)
Oklahoma (3)
Oregon (3)
Pennsylvania (69)
Puerto Rico (3)
Rhode Island (1)
South America (126)
South Carolina (1)
Southern California (192)
Tennessee (6)
Texas (62)
Utah (15)
Virginia (11)
Washington D.C. (10)
Washington State (41)
Wisconsin (8)
67,740 Results for "lilly ventures".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Venture capitalists
Lilly Partners With a16z on $500M VC Fund for Early-Stage Biotechs
The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) with Eli Lilly’s expertise in R&D—plus half a billion in capital from the Big Pharma.
January 10, 2025
·
1 min read
·
Annalee Armstrong
Immunology and inflammation
Lilly’s I&I Push Gains Momentum With Omvoh Expansion
Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according to analysts from BMO Capital Markets.
January 16, 2025
·
2 min read
·
Tristan Manalac
Government
Lilly Wins Medicare Coverage for Zepbound in Sleep Apnea
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to secure CMS coverage for obesity drugs.
January 9, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Venture Fund
January 10, 2025
·
3 min read
GLP-1
Lilly Asks to Join GLP-1 Compounding Lawsuit
Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its interests.
January 3, 2025
·
2 min read
·
Nick Paul Taylor
Collaboration
Lilly Signs Back-to-Back Deals in MASH, Cancer
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals and another for cancer therapies with Australia’s AdvanCell.
February 11, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Lilly Makes $780M+ IPF Play with Mediar Partnership
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early studies have found to be safe and capable of engaging its target.
January 10, 2025
·
2 min read
·
Tristan Manalac
Earnings
Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
January 14, 2025
·
2 min read
·
Dan Samorodnitsky
GLP-1
Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.
February 12, 2025
·
2 min read
·
Annalee Armstrong
Cardiovascular disease
Lilly’s RNA Silencer Lowers Key Cardiovascular Biomarker by Almost 94%
BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in development to date” in the competitive Lp(a) space, where drugs are designed to lower the risk of cardiovascular events such as heart attack and stroke.
March 31, 2025
·
2 min read
·
Tristan Manalac
1 of 6,774
Next
